Toni Raybon
Family · Louisville, KYNPI 1013241843
Payments from drug & device makers
Across 580 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$1K
- Pfizer$951
- Bayer$587
- Boehringer Ingelheim$540
- plus $5K from 32 others
What the payments were for
- Food & beverage$10,86298%
- Education$2412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $1,711 |
| AbbVie | 98 | $1,382 |
| Novo Nordisk | 62 | $1,238 |
| Pfizer | 70 | $951 |
| Bayer | 28 | $587 |
| Boehringer Ingelheim | 40 | $540 |
| Astellas Pharma US Inc | 12 | $496 |
| Johnson & Johnson | 17 | $404 |
| Lilly USA, LLC | 26 | $403 |
| Amgen | 29 | $401 |
| GSK | 27 | $371 |
| Vanda Pharmaceuticals Inc. | 13 | $357 |
| Exact Sciences | 14 | $331 |
| Novartis | 12 | $189 |
| Idorsia Pharmaceuticals US Inc | 4 | $171 |
| Esperion Therapeutics, Inc. | 11 | $143 |
| Axsome Therapeutics, Inc. | 2 | $142 |
| Antares Pharma, Inc. | 7 | $137 |
| Merck | 8 | $130 |
| Otsuka America Pharmaceutical, Inc. | 6 | $127 |
| Phathom Pharmaceuticals, Inc. | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $99 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $86 |
| ANI Pharmaceuticals, Inc. | 5 | $76 |
| Medtronic | 3 | $59 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Verona Pharma, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 1 | $27 |
| Lundbeck LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Abbott | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,103 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 79 | $71,657 |
| VraylarCariprazine Hcl | 42 | $64,268 |
| OzempicSemaglutide | 44 | $44,047 |
| JardianceEmpagliflozin | 27 | $41,076 |
| EliquisApixaban | 40 | $39,105 |
| TrulicityDulaglutide | 23 | $27,018 |
| XareltoRivaroxaban | 14 | $20,804 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $16,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $15,067 |
| LinzessLinaclotide | 14 | $14,452 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 368 | $10,209 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $8,356 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,788 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,689 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $6,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,711 | $94,184133 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,382 | $79,68069 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $540 | $47,35339 claims |
| Novo NordiskOzempic | $1,238 | $44,04744 claims |
| PfizerEliquis | $951 | $39,10540 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $371 | $29,54458 claims |
| Lilly USA, LLCTrulicity | $403 | $27,01823 claims |
| Johnson & JohnsonXarelto | $404 | $20,80414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Louisville
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Shelley WaldmanLouisville$59K
- Esther MuhsLouisville$44K
- Barbra CaveLouisville$41K
- Kayla WilsonLouisville$40K
- Christin ThompsonLouisville$38K
- Wendi HallerLouisville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.